An intestinal stem cell niche in

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• C-terminal binding protein 2 (CtBP2) is implicated in driving intestinal polyposis, particularly in the Apcmin mouse model relevant to human Familial Adenomatous Polyposis.
• Understanding CtBP2's function in adenoma formation is crucial for developing effective CtBP-targeted therapies for Apc-mutated cancers.

Purpose of the Study:

• To investigate the role of CtBP2 gene dosage and activity in intestinal polyposis and tumor-initiating cell (TIC) populations.
• To evaluate the therapeutic potential of a CtBP inhibitor in preclinical models of Apc-mutated neoplasia.

Main Methods:

• Analysis of intestinal epithelia in ApcminCtbp2+/- mice to assess TIC populations and CtBP2 localization.
• Treatment of Apcmin mice with the CtBP inhibitor 4-chloro-hydroxyimino phenylpyruvate (4-Cl-HIPP) to evaluate its effect on TIC populations and polyposis.

Main Results:

• Reduced CtBP2 levels (ApcminCtbp2+/-) significantly decreased intestinal TIC populations.
• CtBP2 mislocalization to the cytoplasm in intestinal crypt stem cells correlated with lower CD133 expression and reduced polyp burden.
• CtBP inhibitor 4-Cl-HIPP administration downregulated TIC populations and decreased intestinal polyposis in Apcmin mice.

Conclusions:

• A critical link exists between intestinal polyposis, TIC populations, and CtBP2 gene dosage or activity.
• Targeting CtBP demonstrates therapeutic promise for the treatment or prevention of Apc-mutated neoplasia.